Xeris Biopharma (NASDAQ:XERS – Get Free Report) and MIRA Pharmaceuticals (NASDAQ:MIRA – Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, analyst recommendations, earnings, valuation and profitability.
Risk & Volatility
Xeris Biopharma has a beta of 1.1, meaning that its stock price is 10% more volatile than the S&P 500. Comparatively, MIRA Pharmaceuticals has a beta of 1.93, meaning that its stock price is 93% more volatile than the S&P 500.
Insider and Institutional Ownership
42.8% of Xeris Biopharma shares are owned by institutional investors. Comparatively, 35.2% of MIRA Pharmaceuticals shares are owned by institutional investors. 6.5% of Xeris Biopharma shares are owned by insiders. Comparatively, 6.7% of MIRA Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Earnings & Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Xeris Biopharma | $222.55 million | 3.43 | -$62.26 million | ($0.30) | -16.27 |
| MIRA Pharmaceuticals | N/A | N/A | -$11.98 million | ($0.51) | -2.41 |
MIRA Pharmaceuticals has lower revenue, but higher earnings than Xeris Biopharma. Xeris Biopharma is trading at a lower price-to-earnings ratio than MIRA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Xeris Biopharma and MIRA Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Xeris Biopharma | -33.69% | N/A | -17.38% |
| MIRA Pharmaceuticals | N/A | -337.44% | -280.58% |
Analyst Recommendations
This is a breakdown of current ratings and recommmendations for Xeris Biopharma and MIRA Pharmaceuticals, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Xeris Biopharma | 0 | 1 | 5 | 0 | 2.83 |
| MIRA Pharmaceuticals | 0 | 0 | 2 | 1 | 3.33 |
Xeris Biopharma currently has a consensus price target of $6.25, suggesting a potential upside of 28.07%. MIRA Pharmaceuticals has a consensus price target of $14.00, suggesting a potential upside of 1,038.21%. Given MIRA Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts plainly believe MIRA Pharmaceuticals is more favorable than Xeris Biopharma.
Summary
MIRA Pharmaceuticals beats Xeris Biopharma on 8 of the 14 factors compared between the two stocks.
About Xeris Biopharma
Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
About MIRA Pharmaceuticals
MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder. In addition, its oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Miami, Florida.
Receive News & Ratings for Xeris Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xeris Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
